W Jiang1, M Li1, F He1, Z Bian1, J Liu2, Q He3, X Wang1, T Sun2, L Zhu1. 1. Department of Orthopedics, Nanjing Medical University, Affiliated Hangzhou Hospital (Hangzhou First People's Hospital), Hangzhou, China. 2. Department of Orthopaedics, General Hospital of Beijing Military Command, Beijing, China. 3. Department of Orthopedics, Shanghai Jiao Tong University affiliated Sixth People's Hospital, Shanghai, China.
Abstract
STUDY DESIGN: Randomized experimental study. OBJECTIVES: The study aimed to investigate the therapeutic efficacy and molecular mechanisms of A-68930 in a rat model of spinal cord injury (SCI)-induced acute lung injury (ALI). SETTING: China. METHODS: The influences of A-68930 on the pulmonary edema, histological changes, proinflammatory cytokines levels, myeloperoxidase (MPO) activity and NLRP3 inflammasome protein expression were estimated. RESULTS: SCI significantly promoted NLRP3 inflammasome activation, increased proinflammatory cytokine productions and MPO activity, and induced pulmonary edema and tissue damage in the SCI group as compared with the control group. A-68930 administration significantly inhibited NLRP3 inflammasome activation and reduced inflammatory cytokines levels and MPO activity. Moreover, A-68930 administration attenuated pulmonary edema and histopathology. CONCLUSION: Our experimental findings indicated that A-68930 exhibited a protective effect on SCI-induced ALI by the alleviations of inflammatory response with the inhibition NLRP3 inflammasome activation 72 h post injury. The present study indicated that A-68930 could be a potentially efficient therapeutic strategy for the treatment of SCI-induced ALI.
STUDY DESIGN: Randomized experimental study. OBJECTIVES: The study aimed to investigate the therapeutic efficacy and molecular mechanisms of A-68930 in a rat model of spinal cord injury (SCI)-induced acute lung injury (ALI). SETTING: China. METHODS: The influences of A-68930 on the pulmonary edema, histological changes, proinflammatory cytokines levels, myeloperoxidase (MPO) activity and NLRP3 inflammasome protein expression were estimated. RESULTS: SCI significantly promoted NLRP3 inflammasome activation, increased proinflammatory cytokine productions and MPO activity, and induced pulmonary edema and tissue damage in the SCI group as compared with the control group. A-68930 administration significantly inhibited NLRP3 inflammasome activation and reduced inflammatory cytokines levels and MPO activity. Moreover, A-68930 administration attenuated pulmonary edema and histopathology. CONCLUSION: Our experimental findings indicated that A-68930 exhibited a protective effect on SCI-induced ALI by the alleviations of inflammatory response with the inhibition NLRP3 inflammasome activation 72 h post injury. The present study indicated that A-68930 could be a potentially efficient therapeutic strategy for the treatment of SCI-induced ALI.
Authors: Susanne Herold; Tannaz Shafiei Tabar; Hermann Janssen; Katrin Hoegner; Maciej Cabanski; Peter Lewe-Schlosser; Jens Albrecht; Frank Driever; Istvan Vadasz; Werner Seeger; Mirko Steinmueller; Juergen Lohmeyer Journal: Am J Respir Crit Care Med Date: 2011-01-28 Impact factor: 21.405
Authors: Maria T Kuipers; Hamid Aslami; John R Janczy; Koenraad F van der Sluijs; Alexander P J Vlaar; Esther K Wolthuis; Goda Choi; Joris J T H Roelofs; Richard A Flavell; Fayyaz S Sutterwala; Paul Bresser; Jaklien C Leemans; Tom van der Poll; Marcus J Schultz; Catharina W Wieland Journal: Anesthesiology Date: 2012-05 Impact factor: 7.892